In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas

Br J Haematol. 2019 Jul;186(1):149-152. doi: 10.1111/bjh.15727. Epub 2018 Dec 19.

Authors

Chiara Tarantelli¹, Eugenio Gaudio¹, Luciano Cascione^{1

2}, Anastasios Stathis³, Emanuele Zucca³, Francesco Bertoni¹

Affiliations

¹ Institute of Oncology Research (IOR), Università della Svizzera italiana (USI), Bellinzona, Switzerland.
² SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
³ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

PMID: 30569468
DOI: 10.1111/bjh.15727

No abstract available

Keywords: T-cell lymphoma; chemotherapy; ibrutinib; idelalisib; lymphomas.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Drug Synergism*
Humans
Isoquinolines / therapeutic use*
Lymphoma / drug therapy*
Piperidines
Purines / therapeutic use
Pyrazoles / therapeutic use
Pyrimidines / therapeutic use
Quinazolinones / therapeutic use

Substances

Antineoplastic Agents
Isoquinolines
Piperidines
Purines
Pyrazoles
Pyrimidines
Quinazolinones
ibrutinib
pixantrone
Adenine
idelalisib